Neuroleptic malignant syndrome: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett m (Typo) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Neuroleptic malignant syndrome''' is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see [[antipsychotic agent]]s) which are in turn associated with [[Biogenic amine receptor|dopaminergic receptor]] blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; [[tremor]]; high [[fever]]; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."<ref>{{MeSH}}</ref><ref name="isbn0-07-067439-6">{{cite book |author=Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice |title=Principles of Neurology |publisher=McGraw-Hill, Health Professions Division |location=New York |year=1997 |pages=1199 |isbn=0-07-067439-6 |oclc= |doi=}}</ref><ref name="pmid9735957">{{cite journal |author=Pelonero AL, Levenson JL, Pandurangi AK |title=Neuroleptic malignant syndrome: a review |journal=Psychiatr Serv |volume=49 |issue=9 |pages=1163-72 |year=1998 |pmid=9735957 |doi= |url=http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=9735957}}</ref> | '''Neuroleptic malignant syndrome''' is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see [[antipsychotic agent]]s) which are in turn associated with [[Biogenic amine receptor|dopaminergic receptor]] blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; [[tremor]]; high [[fever]]; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."<ref>{{MeSH}}</ref><ref name="isbn0-07-067439-6">{{cite book |author=Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice |title=Principles of Neurology |publisher=McGraw-Hill, Health Professions Division |location=New York |year=1997 |pages=1199 |isbn=0-07-067439-6 |oclc= |doi=}}</ref><ref name="pmid9735957">{{cite journal |author=Pelonero AL, Levenson JL, Pandurangi AK |title=Neuroleptic malignant syndrome: a review |journal=Psychiatr Serv |volume=49 |issue=9 |pages=1163-72 |year=1998 |pmid=9735957 |doi= |url=http://ps.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=9735957}}</ref> | ||
Blockade of the [[Biogenic amine receptor|D2 receptors]], which may be predisposed by genetic polymorphisms of the allele, cause neuroleptic malignant syndrome.<ref name="pmid15094790">{{cite journal |author=Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K |title=Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene |journal=Mol. Psychiatry |volume=9 |issue=3 |pages=293-8 |year=2004 |pmid=15094790 |doi=10.1038/sj.mp.4001422 |url=http://dx.doi.org/10.1038/sj.mp.4001422}}</ref> | |||
==References== | ==References== | ||
Revision as of 06:57, 2 April 2008
Neuroleptic malignant syndrome is "potentially fatal syndrome associated primarily with the use of neuroleptic agents (see antipsychotic agents) which are in turn associated with dopaminergic receptor blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinical features include diffuse muscle rigidity; tremor; high fever; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present."[1][2][3]
Blockade of the D2 receptors, which may be predisposed by genetic polymorphisms of the allele, cause neuroleptic malignant syndrome.[4]
References
- ↑ Anonymous (2024), Neuroleptic malignant syndrome (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Ropper, Allan H.; Adams, Raymond Delacy; Victor, Maurice (1997). Principles of Neurology. New York: McGraw-Hill, Health Professions Division, 1199. ISBN 0-07-067439-6.
- ↑ Pelonero AL, Levenson JL, Pandurangi AK (1998). "Neuroleptic malignant syndrome: a review". Psychiatr Serv 49 (9): 1163-72. PMID 9735957. [e]
- ↑ Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004). "Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene". Mol. Psychiatry 9 (3): 293-8. DOI:10.1038/sj.mp.4001422. PMID 15094790. Research Blogging.